NCT02395263 is a Phase 2 clinical trial of Yuxintine in Major Depressive Disorder (MDD), sponsored by Shanghai Mental Health Center.

Who is sponsoring NCT02395263?

NCT02395263 is sponsored by Shanghai Mental Health Center.

What drugs are being tested in NCT02395263?

Interventions in NCT02395263: Yuxintine.

What condition does NCT02395263 study?

NCT02395263 studies Major Depressive Disorder (MDD).

Is NCT02395263 still recruiting?

NCT02395263 is currently status unknown. Last updated 20 March 2015.

Last reviewed 2015-03-20 · How we verify

NCT02395263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial

Status unknown Phase 2 Last updated 20 March 2015

What this trial tests

Phase 2 trial testing Yuxintine in Major Depressive Disorder (MDD) in 160 participants. Status unknown.

Timeline

1 March 2015

Primary endpoint
1 March 2016

1 April 2016

Quick facts

Lead sponsor	Shanghai Mental Health Center
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	160
Start date	1 March 2015
Primary completion	1 March 2016
Estimated completion	1 April 2016
Sites	10 locations across China

Drugs / interventions tested

Yuxintine — full drug profile →

Conditions studied

Major Depressive Disorder (MDD) — all drugs for Major Depressive Disorder (MDD) →

Sponsor

Shanghai Mental Health Center — full company profile →

Who can join

Adults 18 to 65, any sex, with Major Depressive Disorder (MDD). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The change of total score from baseline in MADRS scale
Time frame: 6 weeks

Sponsor's own description

The purpose of this study is to determine whether Yuxintine Capsule in different doses are effective in the treatment of Depression. And to explore the preliminary information of safety and efficacy of Yuxintine Capsule in the Chinese Patients with Depression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Major Depressive Disorder (MDD)

Currently open trials in the same condition.

NCT07396272 — A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression · Phase 2 · recruiting
NCT07226661 — Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder · Phase 2 · recruiting
NCT07324070 — Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression · NA · recruiting
NCT06972368 — Home-Based tDCS for Depression in BPD · NA · recruiting
NCT07294924 — Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements · recruiting

Other Shanghai Mental Health Center trials

Trials by the same sponsor.

NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02395263 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
Last refreshed: 20 March 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02395263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing